The client was launching a new vaccine and wanted to gain optimal market access in global markets for this product. Asc academics was approached with the request to perform a network meta-analysis that compares the safety profiles of the client’s vaccine with those already on the market, in order to demonstrate the clinical and economical value of the product.
The main challenge was to deal with the uncertainty around the estimates. The robustness of the results of a network meta-analysis depends on factors such as the amount of available literature and the sample size of the trials. In this case, the literature for the comparators of the new vaccine was scarce and the sample sizes of the trials were relatively small.